Galectin Therapeutics (NASDAQ:GALT – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01, FiscalAI reports.
Galectin Therapeutics Price Performance
Galectin Therapeutics stock opened at $3.05 on Monday. The stock has a market capitalization of $200.87 million, a price-to-earnings ratio of -7.09 and a beta of 0.53. Galectin Therapeutics has a 1-year low of $2.03 and a 1-year high of $7.13. The business has a fifty day moving average price of $3.65 and a 200-day moving average price of $3.22.
Analysts Set New Price Targets
GALT has been the topic of several analyst reports. Zacks Research upgraded Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Monday, September 14th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $11.00.
Read Our Latest Research Report on GALT
About Galectin Therapeutics
Galectin Therapeutics is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company’s research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer. Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment.
Featured Stories
- Five stocks we like better than Galectin Therapeutics
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
